We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ProDex Q1 Earnings Preview: Can Strong Sales Momentum Sustain Growth?
Read MoreHide Full Article
Key Takeaways
PDEX's Q1 earnings are expected to rise 8.1% to 67 cents per share, with revenues growing 10.1% to $20.4M.
Fiscal Q4 sales rose 17%, while gross margin improved to 35% from 20%, reflecting a favorable product mix.
Customer concentration of 78%, lower backlog and APM integration risks could challenge PDEX's growth momentum.
ProDex, Inc. (PDEX - Free Report) is expected to report first-quarter fiscal 2027 results soon. The surgical-device manufacturer has entered the first quarter following robust fiscal 2026 growth, supported by higher medical-device sales and improved gross margins. Investors will assess the sustainability of this momentum, with particular attention to customer concentration, expense management and progress on integrating the recent acquisition.
The Zacks Consensus Estimate for fiscal first-quarter earnings is pegged at 67 cents per share, indicating 8.1% year-over-year growth. The consensus mark for revenues is pinned at $20.4 million, calling for a 10.1% increase from the year-ago quarter’s level.
PDEX shares gained 17.9% from June 30 through September-end, outperforming the Medical - Dental Supplies industry, which advanced 4.8%, and the S&P 500, which rose 1.6%.
PDEX delivered an average earnings surprise of 26.93% for the trailing four quarters.
Image Source: Zacks Investment Research
Quarterly Drivers and Challenges
Medical-Device Demand and Margins: ProDex's fourth-quarter fiscal 2026 results provide an encouraging starting point. Net sales increased 17% year over year to $20.4 million, while gross profit more than doubled to $7.1 million from $3.5 million. Gross margin improved to 35% from 20%, reflecting favorable product mix and better absorption of indirect manufacturing costs. Net income increased to $2.9 million, or 89 cents per share, from $1.2 million, or 36 cents per share.
This rising trend for sales and improved manufacturing economics is likely to have supported earnings growth in the first quarter. Investors will assess whether the company was able to sustain its recent margin gains in the September quarter.
Customer Concentration and Order Visibility: ProDex generated 78% of fiscal 2026 sales from its largest customer, while its three largest customers accounted for 92%. The extension of the supply agreement for surgical handpieces with its largest customer through calendar 2028 provides better near-term sales visibility. The positive impact is expected to have extended into the first quarter as well.
The company's backlog declined to $32.9 million as of June 30, 2026, from $50.4 million a year earlier. The company expects to deliver substantially all its backlog, together with certain orders received afterward, during fiscal 2027. Investors are likely to focus on the pace of shipments and new bookings on the first-quarter earnings call to assess revenue visibility.
Acquisition & Execution Risks: ProDex acquired Advanced Precision Machining in February 2026 to support manufacturing capacity and expand into aerospace and defense. The acquisition not only creates diversification opportunities but also introduces integration and compliance requirements. Higher operating expenses and supply-chain disruptions may have constrained profitability during the first quarter.
Our proven model does not conclusively predict an earnings beat for PDEX this time around. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that is not the case here, as you can see below.
Earnings ESP: ProDex has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Glaukos reported second-quarter 2026 earnings per share of 14 cents, which beat the Zacks Consensus Estimate by 50.00%. Revenues of $186 million surpassed the Zacks Consensus Estimate by 24.1%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 25.87%.
Edward Lifesciences reported second-quarter 2026 adjusted EPS of 78 cents, which beat the Zacks Consensus Estimate by 6.85%. Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 2.45%.
Edward Lifesciences has an estimated long-term earnings growth rate of 12.7%. EW’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.49%.
Globus Medical reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%
View the Zacks #1 Rank List
Image: Shutterstock
ProDex Q1 Earnings Preview: Can Strong Sales Momentum Sustain Growth?
Key Takeaways
ProDex, Inc. (PDEX - Free Report) is expected to report first-quarter fiscal 2027 results soon. The surgical-device manufacturer has entered the first quarter following robust fiscal 2026 growth, supported by higher medical-device sales and improved gross margins. Investors will assess the sustainability of this momentum, with particular attention to customer concentration, expense management and progress on integrating the recent acquisition.
The Zacks Consensus Estimate for fiscal first-quarter earnings is pegged at 67 cents per share, indicating 8.1% year-over-year growth. The consensus mark for revenues is pinned at $20.4 million, calling for a 10.1% increase from the year-ago quarter’s level.
PDEX shares gained 17.9% from June 30 through September-end, outperforming the Medical - Dental Supplies industry, which advanced 4.8%, and the S&P 500, which rose 1.6%.
PDEX delivered an average earnings surprise of 26.93% for the trailing four quarters.
Image Source: Zacks Investment Research
Quarterly Drivers and Challenges
Medical-Device Demand and Margins: ProDex's fourth-quarter fiscal 2026 results provide an encouraging starting point. Net sales increased 17% year over year to $20.4 million, while gross profit more than doubled to $7.1 million from $3.5 million. Gross margin improved to 35% from 20%, reflecting favorable product mix and better absorption of indirect manufacturing costs. Net income increased to $2.9 million, or 89 cents per share, from $1.2 million, or 36 cents per share.
This rising trend for sales and improved manufacturing economics is likely to have supported earnings growth in the first quarter. Investors will assess whether the company was able to sustain its recent margin gains in the September quarter.
Customer Concentration and Order Visibility: ProDex generated 78% of fiscal 2026 sales from its largest customer, while its three largest customers accounted for 92%. The extension of the supply agreement for surgical handpieces with its largest customer through calendar 2028 provides better near-term sales visibility. The positive impact is expected to have extended into the first quarter as well.
The company's backlog declined to $32.9 million as of June 30, 2026, from $50.4 million a year earlier. The company expects to deliver substantially all its backlog, together with certain orders received afterward, during fiscal 2027. Investors are likely to focus on the pace of shipments and new bookings on the first-quarter earnings call to assess revenue visibility.
Acquisition & Execution Risks: ProDex acquired Advanced Precision Machining in February 2026 to support manufacturing capacity and expand into aerospace and defense. The acquisition not only creates diversification opportunities but also introduces integration and compliance requirements. Higher operating expenses and supply-chain disruptions may have constrained profitability during the first quarter.
Pro-Dex, Inc. Price and EPS Surprise
Pro-Dex, Inc. price-eps-surprise | Pro-Dex, Inc. Quote
What Our Model Unveils for ProDex Stock
Our proven model does not conclusively predict an earnings beat for PDEX this time around. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that is not the case here, as you can see below.
Earnings ESP: ProDex has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: PDEX carries a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Some stocks worth considering from the broader medical space are Glaukos (GKOS - Free Report) , Edward Lifesciences (EW - Free Report) and Globus Medical (GMED - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos reported second-quarter 2026 earnings per share of 14 cents, which beat the Zacks Consensus Estimate by 50.00%. Revenues of $186 million surpassed the Zacks Consensus Estimate by 24.1%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 25.87%.
Edward Lifesciences reported second-quarter 2026 adjusted EPS of 78 cents, which beat the Zacks Consensus Estimate by 6.85%. Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 2.45%.
Edward Lifesciences has an estimated long-term earnings growth rate of 12.7%. EW’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.49%.
Globus Medical reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%